RELATIONSHIP OF TIME TO RELAPSE (TTR) AND SURVIVAL POST RELAPSE (SPR): EXPLORATION OF RISK FACTORS FROM THE FOLLOW-UP DATASET OF A RANDOMIZED PBO-CONTROLLED STUDY OF OREGOVOMAB (OV) AS A CONSOLIDATION THERAPY FOR PATIENTS WITH ADVANCED OVARIAN CANCER (OC)